On the other hand, melatonin was shown to inhibit AKT/mTOR signaling in models of ovarian cancer [104], breast cancer [218], hepatoma [219], and melanoma [220], where AKT/mTOR are aberrantly hyperactivated and contribute to carcinogenesis [221]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.